08:29 AM EDT, 09/17/2025 (MT Newswires) -- Astria Therapeutics ( ATXS ) said Wednesday its STAR-0310 showed a half-life of up to 68 days, consistent with administration every six months, along with cytokine suppression lasting for at least 20 weeks during its phase 1a trial.

Shares of the company were up more than 4% in recent Wednesday premarket activity.

The company further said that STAR-0310 was observed to be well-tolerated at all dose levels, with no serious treatment-emergent adverse events or discontinuations.

STAR-0310 is a YTE half-life extended monoclonal antibody antagonist of OX40, a type of protein.

Price: 7.60, Change: +0.33, Percent Change: +4.54